TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

14 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis

26 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

06 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)

28 Dec 2022 13:48:07 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

10 Nov 2022 07:30:01 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update

08 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

26 Oct 2022 07:30:58 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis

13 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

09 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine

25 Aug 2022 07:30:47 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

08 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business Update

05 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology

27 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

03 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS

31 May 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

26 May 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

20 May 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference

26 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL

15 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting

06 Apr 2022 07:30:00 By Nasdaq GlobeNewswire